We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Warns See Clear Company for Record-Keeping Problems

FDA Warns See Clear Company for Record-Keeping Problems

June 23, 2017

The FDA issued a warning letter to contact lens manufacturer The See Clear Company, citing problems with its complaint and corrective action procedures.

The agency conducted an inspection of the company’s Norcross, Georgia, facility during October and November and issued a Form 483. Although See Clear promised to correct these problems, the agency has no way to determine whether the company’s efforts have been effective, and the company response did not include documentation of corrections it made.

The initial inspection found the company’s corrective and preventive action procedure does not include verifying and validating corrective actions or recording changes in the procedure. The FDA also faulted the company’s complaint procedure, noting that it does not cover how to determine when investigations are necessary or appropriate methods of handling customer complaints or maintaining complaint files.

The firm also had no established procedures for accepting incoming products or documenting acceptance or rejection, according to the warning letter, and the facility could not provide complete distribution records or define the firm’s control over contractors. The company’s written procedures for nonconforming products do not reflect current practices, and the firm could not provide complete device history records for one lot of its Diamond Brand soft contact lenses.

The company also failed to document personnel training as well as the dates of both quality audits and approval documents, and the company’s management was unable to provide dates, agendas and attendance records for 2014 and 2015 review meetings, according to the FDA.

View today's stories

Medical Devices Quality

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

  • MedTrace Receives U.S. Patent for Heart Modeling Method

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing